BARCELONA, Spain — In the phase 2 ARCHER trial, ANX007, a novel C1q inhibitor with neuroprotective properties, showed consistent protection against loss of visual acuity in eyes with geographic atrophy.

One-year study results as well as 18-month extension data were presented by Usha Chakravarthy, MD, PhD, at the Euretina Congress.

ANX007 (Annexon Biosciences) was administered intravitreally every month or every other month and compared with a sham injection.

“The primary outcome was the change in GA area measured by fundus autofluorescence, but there were key secondary outcomes that included best-corrected visual acuity and low luminance acuity,” Chakravarthy said.

Visual acuity loss was significantly reduced in the two treatment arms compared with the sham arm. More than 20% of sham eyes experienced a loss of 15 letters compared with 5.6% of the eyes treated every month and 9.8% of eyes treated every other month. Similar findings were observed with low luminance visual acuity.

“After 12 months, when the patients came off treatment, these event rates of 15 letter losses started to accumulate faster and reached a similar frequency as the sham arm,” Chakravarthy said…..

Read more: https://www.healio.com/news/ophthalmology/20241209/archer-trial-shows-benefit-of-anx007-on-vision-loss-in-geographic-atrophy?utm_source=selligent&utm_medium=email&utm_campaign=news

Source: Healio